Novo Nordisk agreed to acquire global rights to zaltenibart (OMS‑906), an antibody that inhibits MASP‑3 in the complement pathway, from Omeros in a deal valued at up to $2.1 billion including milestones and royalties. Novo will pursue Phase 3 testing in paroxysmal nocturnal hemoglobinuria (PNH) and explore additional rare blood and kidney disorders where complement dysregulation is causal. Omeros, which had paused late‑stage investment in the program to preserve capital, will receive upfront and near‑term payments and retain a royalty stream contingent on future commercial success. Analysts noted the deal accelerates Novo’s push into rare‑disease complement biology and gives the company a differentiated mechanism to challenge incumbent C5 inhibitors.